CN1193003C - 作为IL－1β与TNF－α抑制剂的氨基二苯酮 - Google Patents

作为IL－1β与TNF－α抑制剂的氨基二苯酮 Download PDF

Info

Publication number
CN1193003C
CN1193003C CNB008177767A CN00817776A CN1193003C CN 1193003 C CN1193003 C CN 1193003C CN B008177767 A CNB008177767 A CN B008177767A CN 00817776 A CN00817776 A CN 00817776A CN 1193003 C CN1193003 C CN 1193003C
Authority
CN
China
Prior art keywords
compound
chloro
phenylamino
methylbenzophenone
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008177767A
Other languages
English (en)
Chinese (zh)
Other versions
CN1413186A (zh
Inventor
E·R·奥特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of CN1413186A publication Critical patent/CN1413186A/zh
Application granted granted Critical
Publication of CN1193003C publication Critical patent/CN1193003C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C325/00—Thioaldehydes; Thioketones; Thioquinones; Oxides thereof
    • C07C325/02—Thioketones; Oxides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB008177767A 1999-12-06 2000-11-29 作为IL－1β与TNF－α抑制剂的氨基二苯酮 Expired - Fee Related CN1193003C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16933399P 1999-12-06 1999-12-06
US60/169,333 1999-12-06

Publications (2)

Publication Number Publication Date
CN1413186A CN1413186A (zh) 2003-04-23
CN1193003C true CN1193003C (zh) 2005-03-16

Family

ID=22615235

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008177767A Expired - Fee Related CN1193003C (zh) 1999-12-06 2000-11-29 作为IL－1β与TNF－α抑制剂的氨基二苯酮

Country Status (18)

Country Link
US (1) US6541670B2 (enExample)
EP (1) EP1237845B1 (enExample)
JP (1) JP4684515B2 (enExample)
KR (1) KR20020071876A (enExample)
CN (1) CN1193003C (enExample)
AT (1) ATE362912T1 (enExample)
AU (1) AU776395B2 (enExample)
BR (1) BR0016164A (enExample)
CA (1) CA2393312C (enExample)
CZ (1) CZ20021940A3 (enExample)
DE (1) DE60034961T2 (enExample)
ES (1) ES2287040T3 (enExample)
HU (1) HUP0203813A3 (enExample)
MX (1) MXPA02005604A (enExample)
NZ (1) NZ519172A (enExample)
PL (1) PL356049A1 (enExample)
RU (1) RU2260422C2 (enExample)
WO (1) WO2001042189A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
ES2368824T3 (es) * 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
WO2001090074A2 (en) 2000-05-22 2001-11-29 Leo Pharma A/S BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)
EP2070911A2 (en) 2000-07-18 2009-06-17 Bone Care International, Inc. Stabilized 1Alpha-Hydroxy vitamin D
EP1313697B1 (en) 2000-08-29 2005-11-30 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US20020165286A1 (en) * 2000-12-08 2002-11-07 Hanne Hedeman Dermal anti-inflammatory composition
GB0107368D0 (en) * 2001-03-23 2001-05-16 Novartis Ag Organic compounds
CA2458611C (en) 2001-08-28 2012-05-29 Leo Pharma A/S Aminobenzophenones as interleukin 1-beta and tumour necrosis factor-alpha inhibitors
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
ATE349210T1 (de) 2002-07-09 2007-01-15 Boehringer Ingelheim Pharma Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
CN1753861A (zh) * 2002-12-20 2006-03-29 利奥制药有限公司 新颖的氨基二苯酮化合物
DE602004027504D1 (de) 2003-07-24 2010-07-15 Leo Pharma As Aminobenzophenonverbindungen
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
WO2006014549A2 (en) * 2004-07-07 2006-02-09 Nobex Corporation Synthesis of azo bonded immunoregulatory compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
ATE455768T1 (de) * 2004-12-13 2010-02-15 Leo Pharma As Triazolsubstituierte aminobenzophenonverbindungen
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2206534A1 (de) 2008-10-09 2010-07-14 c-a-i-r biosciences GmbH Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten
ES2796530T3 (es) * 2009-10-26 2020-11-27 Prometheus Biosciences Inc Ensayos para la detección de fármacos anti-TNF y autoanticuerpos
JP6218229B2 (ja) 2011-12-28 2017-10-25 京都府公立大学法人 角膜内皮細胞の培養正常化
WO2015050984A1 (en) * 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
EP3069732B1 (en) 2013-11-14 2023-07-12 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57177058A (en) 1981-04-24 1982-10-30 Hodogaya Chem Co Ltd Novel fluoran compound
WO1990015534A1 (en) * 1989-06-13 1990-12-27 Smithkline Beecham Corporation Monokine activity interference
RU2037481C1 (ru) * 1989-10-27 1995-06-19 Американ Хоум Продактс Корпорейшн Производные замещенной бензоилбензолбифенил- или 2-оксазолалкановой кислоты или их фармакологически приемлемые соли и способ их получения
JPH08104817A (ja) * 1994-10-03 1996-04-23 Nippon Soda Co Ltd 新規なフルオラン化合物及びそれを用いた発色性記録材料
GB9701453D0 (en) * 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
EP1029851B1 (en) * 1997-10-14 2005-04-20 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
JPH11217387A (ja) * 1998-01-27 1999-08-10 Yamada Chem Co Ltd フルオラン化合物及びこれを用いた発色性記録材料
WO2001005744A1 (en) * 1999-07-16 2001-01-25 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Novel aminobenzophenones
WO2001090074A2 (en) * 2000-05-22 2001-11-29 Leo Pharma A/S BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)

Also Published As

Publication number Publication date
US6541670B2 (en) 2003-04-01
PL356049A1 (en) 2004-06-14
NZ519172A (en) 2004-03-26
ES2287040T3 (es) 2007-12-16
WO2001042189A1 (en) 2001-06-14
DE60034961D1 (de) 2007-07-05
JP4684515B2 (ja) 2011-05-18
ATE362912T1 (de) 2007-06-15
HK1053463A1 (en) 2003-10-24
EP1237845A1 (en) 2002-09-11
KR20020071876A (ko) 2002-09-13
MXPA02005604A (es) 2004-09-10
CZ20021940A3 (cs) 2003-01-15
US20030013770A1 (en) 2003-01-16
CN1413186A (zh) 2003-04-23
JP2003516377A (ja) 2003-05-13
RU2260422C2 (ru) 2005-09-20
EP1237845B1 (en) 2007-05-23
AU1693501A (en) 2001-06-18
HUP0203813A2 (hu) 2003-03-28
CA2393312C (en) 2011-07-12
DE60034961T2 (de) 2008-01-24
HUP0203813A3 (en) 2008-03-28
AU776395B2 (en) 2004-09-09
CA2393312A1 (en) 2001-06-14
BR0016164A (pt) 2002-08-13
RU2002118113A (ru) 2004-02-20

Similar Documents

Publication Publication Date Title
CN1193003C (zh) 作为IL－1β与TNF－α抑制剂的氨基二苯酮
CN1188388C (zh) 作为白介素和肿瘤坏死因子tnf抑制剂的氨基二苯酮
CN1239485C (zh) 作为IL－1β和TNF－α抑制剂的二苯酮类
CN1282640C (zh) N－芳基苯乙酰胺衍生物及包含所述化合物的药物组合物
CN1181048C (zh) 作为IL-1β和TNF-α的抑制剂的氨基二苯酮
CN1210250C (zh) 苯衍生物、其制备方法以及含有它们的药用组合物
CN101056845A (zh) 取代的苯胺衍生物
CN1167667C (zh) 用作IL-1β和TNF-α抑制剂的氨基二苯酮化合物
CN1636967A (zh) 新颖化合物，其用途及制法
CN1500081A (zh) 乙内酰硫脲及其在治疗糖尿病方面的用途
CN1950348A (zh) 治疗中枢神经系统障碍的取代的吗啉化合物
CN1929834A (zh) 吲哚－1－基乙酸衍生物
CN1805921A (zh) 选择性雄激素受体调节剂的前药及其使用方法
CN1249025C (zh) 作为IL－1β和TNF－α的抑制剂的氨基二苯酮
CN1231459C (zh) 新型氨基二苯酮
CN1665778A (zh) 羟基四氢－萘基脲衍生物
CN1795179A (zh) 新的咪唑衍生物、其制备方法和其作为药物的用途
CN1284777C (zh) 5元杂环化合物、它们的制备和作为药物的应用
CN1705642A (zh) 新颖的n－羟基硫脲,脲和酰胺化合物及包括其的药物组合物
CN1561327A (zh) 新的氨基苯酰苯类化合物
CN1283622C (zh) 环己基(烷基)－丙醇胺及其制备方法和含有它们的药物组合物
CN1247523C (zh) 取代1－和2－萘酚曼尼希碱
HK1053463B (en) Aminobenzophenones as inhibitors of il-1b and tnf-a
CN1823039A (zh) 氨基磺酸环状氨基苯基酯衍生物
HK1047273B (en) Aminobenzophenones as inhibitors of il-1b and tnf-a

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050316

Termination date: 20121129